首页|Routine blood tests to predict liver fibrosis in chronic hepatitis C
Routine blood tests to predict liver fibrosis in chronic hepatitis C
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
AIM:To verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C,compared with other noninvasive tests.METHODS:This retrospective cohort study included 237 consecutive patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treatment.FibroQ,aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR),AST to platelet ratio index,cirrhosis discriminant score,age-platelet index (API),Pohl score,FIB-4 index,and Lok's model were calculated and compared.RESULTS:FibroQ,FIB-4,AAR,API and Lok's model results increased significantly as fibrosis advanced (analysis of variance test:P ＜ 0.001).FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests.CONCLUSION:FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.
Liver fibrosisNoninvasive testFibroQAspartate aminotransferaseAlanine aminotransferaseFIB-4 indexAspartate aminotransferase to platelet ratio indexLok's modelCirrhosis discriminant scorePohl score
Yung-Yu Hsieh、Shui-Yi Tung、Kamfai Lee、Cheng-Shyong Wu、Kuo-Liang Wei、Chien-Heng Shen、Te-Sheng Chang、Yi-Hsiung Lin
展开 >
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Chang Gung University College of Medicine, Taoyuan 333, Taiwan
Chiayi School, Chang Gung Institute of Technology, Chiayi 613, Taiwan
Department of Pathology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Department of Health Care Administration, Taiwan Shoufu University, Tainan 721, Taiwan
NETL
NSTL
万方数据
维普
